Opin vísindi

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study

Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study


Titill: Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study
Höfundur: Safreed-Harmon, Kelly
Hetherington, Kristina L.
Aleman, Soo
Alho, Hannu
Dalgard, Olav
Frisch, Tove
Gottfredsson, Magnus   orcid.org/0000-0003-2465-0422
Weis, Nina
Lazarus, Jeffrey V.
Útgáfa: 2018-01-30
Tungumál: Enska
Umfang: e0190146
Háskóli/Stofnun: Háskóli Íslands
University of Iceland
Svið: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Deild: Læknadeild (HÍ)
Faculty of Medicine (UI)
Birtist í: PLoS ONE;13(1)
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0190146
Efnisorð: Hepatitis C virus; Drug therapy; Prisons; Lifrarbólga C; Lyfjameðferð; Fangelsi
URI: https://hdl.handle.net/20.500.11815/867

Skoða fulla færslu

Tilvitnun:

Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, et al. (2018) Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS ONE 13(1): e0190146. https://doi.org/10.1371/journal.pone.0190146

Útdráttur:

Background and aims In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat. Methods Fourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country. Results Stakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly. Conclusion The Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.

Leyfi:

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:


Fletta

Um vefinn

Reikningurinn minn